Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBITDA: 2020-2024

Historic EBITDA for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to -$73.3 million.

  • Monte Rosa Therapeutics' EBITDA fell 14.65% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year increase of 116.65%. This contributed to the annual value of -$73.3 million for FY2024, which is 46.21% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its EBITDA stood at -$73.3 million for FY2024, which was up 46.21% from -$136.3 million recorded in FY2023.
  • Monte Rosa Therapeutics' EBITDA's 5-year high stood at -$36.9 million during FY2020, with a 5-year trough of -$136.3 million in FY2023.
  • In the last 3 years, Monte Rosa Therapeutics' EBITDA had a median value of -$108.2 million in 2022 and averaged -$106.0 million.
  • In the last 5 years, Monte Rosa Therapeutics' EBITDA plummeted by 102.85% in 2021 and then soared by 46.21% in 2024.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' EBITDA stood at -$36.9 million in 2020, then plummeted by 102.85% to -$74.9 million in 2021, then slumped by 44.46% to -$108.2 million in 2022, then fell by 25.96% to -$136.3 million in 2023, then soared by 46.21% to -$73.3 million in 2024.